Clinical trials: SBRT
Pancreatic Cancer
GTX-RT in Borderline Resectable Pancreatic Cancer
The purpose of this study is to find out if a program of intensive chemotherapy with gemcitabine, docetaxel and capecitabine followed by an advanced form of focused radiation aimed at participant's tumor followed by more…
- Trial name
- NCT01754623
- Testing
- Capecitabine, Gemcitabine, Docetaxel
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Bone Cancer
Evaluating Stereotactic Body Radiation Therapy for Oligometastatic Disease of the Bone
This research study is studying a form of radiation therapy called stereotactic body radiation therapy or SBRT as a possible treatment for Cancer that has spread to the spine or other bone
- Trial name
- NCT02880319
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Stereotactic Linear Accelerator
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Dana-Farber Cancer Institute
Inoperable Stage I/II Non-small Cell Lung Cancer
A Phase I/II Trial of Stereotactic Body Radiation Therapy
The purpose of this study is to use SBRT in patients with early stage lung cancer and find out what effects (good and bad) SBRT has on their cancer.
- Trial name
- SBRT (NCT00591838)
- Testing
- Stereotactic Body Radiation Therapy (SBRT)
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Washington University School of Medicine
Lung Cancer
Stereotactic Body Radiation Therapy in Stage II/III Non Small Cell Lung Cancer
It is apparent that local control for Non-small Cell Lung Cancer (NSCLC) remains a significant problem. Conventional radiation therapy techniques have limitations for the dose that can be delivered to a chest tumor mass due to…
- Trial name
- NCT01657617
- Testing
- Boost Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Ronald McGarry
Prostate Cancer
Randomized Trial of Image -Guided Stereotactic Radiation Therapy (IG-SRT) in Prostate Cancer
Patients with low-risk or favorable intermediate-risk prostate cancer as defined by 1.2016 NCCN criteria will be eligible to participate on this study.
- Trial name
- NCT02911922
- Testing
- Endorectal Balloon, Rectal Spacer, Radiation therapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Weill Medical College of Cornell University
Pancreatic Cancer, Pancreatic Adenocarcinoma
Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates
The objective of this study is to estimate the R0 resection rate in patients with Resectable Pancreatic Ductal Adenocarcinoma (R-PDAC) as well as those with Resectable Pancreatic Ductal Adenocarcinoma (BR-PDAC) independently in…
- Conditions
- Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreas Ductal Adenocarcinoma
- Trial name
- NCT02723331
- Testing
- Nab paclitaxel, Gemcitabine
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Academic Thoracic Oncology Medical Investigators Consortium
Prostate Cancer
Hypofractionated SBRT For Prostate Cancer
The purpose of this study is to determine, in both low-risk and intermediate-risk cohorts, the rates of acute and late grade 3 or higher gastrointestinal and genitourinary toxicity observed during a 24 month follow up and to…
- Trial name
- NCT00977860
- Testing
- Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 163 people
- Sponsor
- Adam Olson
Hepatocellular Carcinoma
Hypoxic Changes in Hepatocellular Carcinoma (HCC) Following Trans Arterial Chemo Embolization and Stereotactic Radiation: Fluorine18 (18F) Fluoromisonidazole (FMISO) Imaging
[18F] FMISO Positron Emission Tomography (PET) to determine hypoxia in patients with HCC treated with TACE.
- Trial name
- NCT03303469
- Testing
- FMISO
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Alabama at Birmingham
Colorectal Cancer, Colorectal Neoplasms
AMP-224, a PD-1 Inhibitor, With Stereotactic Body Radiation Therapy in Metastatic Colorectal Cancer
Background: T-cells are white blood cells that can find and kill germs and tumors. Cancer can keep T-cells from working. Researchers think a new drug called AMP-224 might help the T-cells in people with cancer.
- Conditions
- Colorectal Cancer, Colorectal Neoplasms, Colorectal Carcinoma
- Trial name
- NCT02298946
- Testing
- AMP-224, Stereotactic Body Radiation Therapy(SBRT), Cyclophosphamide
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma
Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival
This randomized phase II/III trial studies how well standard of care therapy with stereotactic radiosurgery and/or surgery works and compares it to standard of care therapy alone in treating patients with breast cancer that has…
- Conditions
- Anatomic Stage IV Breast Cancer American Joint Committee on Cancer (AJCC) v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Liver
- Trial name
- NCT02364557
- Testing
- Stereotactic Body Radiotherapy, Surgery
- Where
- 162 sites in United States, Canada and 2 more
- Volunteers
- 129 people
- Sponsor
- NRG Oncology
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
High-Dose Stereotactic Radiation for Prostate Cancer
This clinical trial studies high-dose stereotactic body radiation therapy (SBRT) in treating patients with low-, intermediate-, or high-risk localized prostate cancer.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01664130
- Testing
- stereotactic body radiation therapy, quality-of-life assessment, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Case Comprehensive Cancer Center
Metastatic Cancer, Pain
Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Patients With Localized Spinal Metastasis
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue.
- Conditions
- Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00855803
- Testing
- radiation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- University of Texas Southwestern Medical Center
Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
This phase II trial compares the effect of adding radiation therapy to an immunotherapy drug called pembrolizumab versus pembrolizumab alone in treating patients with urothelial cancer that has spread from where it first started…
- Conditions
- Metastatic Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Stage IV Bladder Cancer AJCC v8
- Trial name
- NCT04936230
- Testing
- Biospecimen Collection, Bone Scan, Computed Tomography
- Where
- 83 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
MRI-guided Stereotactic Body Radiotherapy (SBRT) With Simultaneous Integrated Boost for Prostate Cancer
Radiation is delivered to the prostate and seminal vesicles in 5 treatment sessions (fractions). Doses ranging from 35-45 Gy in 5 fractions have demonstrated good outcomes with acceptable toxicity.
- Trial name
- SIBRT (NCT03664193)
- Testing
- SIBRT
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Weill Medical College of Cornell University
Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma
RElugolix VErsus LeUprolide Cardiac Trial
This clinical trial investigates the impact of prostate cancer treatment, specifically androgen deprivation therapy (ADT), on the heart and coronary vessels among men with localized, non-metastatic prostate cancer undergoing…
- Conditions
- Biochemically Recurrent Prostate Carcinoma, Localized Prostate Carcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8
- Trial name
- REVELUTION (NCT05320406)
- Testing
- Radiation therapy, Leuprolide, Relugolix
- Where
- 4 sites in United States
- Volunteers
- 94 people
- Sponsor
- Emory University
Breast Cancer, Metastatic
Study for Using Radiosurgery on Limited Metastases of Breast Cancer
The purpose of this study is to evaluate whether radiosurgery, along with standard chemotherapy, immunotherapy (the treatment of cancer by modulating the immune system and immune response), or hormonal therapy, affects the…
- Trial name
- NCT00167414
- Testing
- Hypofractionated Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Rochester
Liver Cancer
Stereotactic Radiation Therapy in Treating Patients With Advanced Liver Cancer
This is a phase I trial studying the side effects and best dose of stereotactic radiation therapy (SRT) in treating patients with advanced liver cancer.
- Trial name
- NCT00607828
- Testing
- stereotactic body radiation therapy
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Nebraska
Hepatocellular Carcinoma, HCC
Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant
This study will compare stereotactic body radiation therapy (SBRT) to trans-arterial chemoembolization (TACE) as a bridging strategy for patients with HCC undergoing liver transplantation.
- Trial name
- SBRTvsTACE (NCT03960008)
- Testing
- Stereotactic Body Radiation Therapy (SBRT), Trans-Arterial Chemoembolization (TACE), Doxorubin
- Where
- 5 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Lahey Clinic
Non Small Cell Lung Cancer, Lung Cancer
FLT3 Ligand, CD40 Agonist Antibody, and Stereotactic Radiotherapy
The purpose of this study is to test a new way of treating the most common form of lung cancer. The investigators are testing a combination of radiotherapy with two new forms of immunotherapy.
- Trial name
- FLT3 (NCT04491084)
- Testing
- FLT3 Ligand (CDX-301), anti-CD40 antibody (CDX-1140), SBRT
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Albert Einstein College of Medicine
Histological or Cytological Diagnosis of Pancreatic Carcinoma
A Pilot Study to Evaluate Radiotherapy-Induced Anti-Tumor Immunity in Metastatic Carcinoma of the Pancreas
Primary Objective: To estimate the rate at which radiotherapy to the primary or a metastatic lesion produces an immune response in patients with metastatic carcinoma of the pancreas.
- Trial name
- NCT01985958
- Testing
- Radiation therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Abramson Cancer Center at Penn Medicine